Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vofatamab + actinium-225
- Development stage
- Discontinued
- Lead developer
- AstraZeneca
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Vofatamab + actinium-225 (FPI-1966)** is a radiopharmaceutical composed of vofatamab, a human IgG1 monoclonal antibody that targets fibroblast growth factor receptor 3 (FGFR3), conjugated via the Fast-Clear linker to actinium-225, a potent alpha-emitting radioisotope. This targeted alpha therapy is designed to deliver cytotoxic alpha radiation specifically to tumor cells that express FGFR3, an oncogenic driver overexpressed in several solid tumors, notably bladder, head and neck, and ovarian cancers. Developed for precision oncology, FPI-1966 aims to selectively irradiate and eradicate cancer cells while sparing normal tissue. Fusion Pharmaceuticals is the main developer, with ongoing Phase 1/2 clinical trials to evaluate safety, tolerability, dosimetry, pharmacokinetics, and preliminary efficacy in patients with advanced FGFR3-expressing solid tumors[1][2][3][4][7][10].
- Other names
- actinium Ac 225 vofatamab
02
Targets
FGFR3 (Fibroblast growth factor receptor 3)
Beyond the preview
Go deeper on vofatamab + actinium-225.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vofatamab + actinium-225.